S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

NASDAQ:XTLB - X T L Biopharmaceuticals Stock Price, Forecast & News

0.00 (0.00 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
Now: $1.30
50-Day Range
MA: $1.30
52-Week Range
Now: $1.30
Average Volume12,973 shs
Market Capitalization$6.68 million
P/E Ratio8.67
Dividend YieldN/A
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XTLB



Sales & Book Value

Annual SalesN/A
Cash Flow$0.58 per share
Book Value$1.62 per share


Net Income$2.99 million


Market Cap$6.68 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive XTLB News and Ratings via Email

Sign-up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.

X T L Biopharmaceuticals (NASDAQ:XTLB) Frequently Asked Questions

What is X T L Biopharmaceuticals' stock symbol?

X T L Biopharmaceuticals trades on the NASDAQ under the ticker symbol "XTLB."

When did X T L Biopharmaceuticals' stock split? How did X T L Biopharmaceuticals' stock split work?

X T L Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of X T L Biopharmaceuticals stock prior to the reverse split would have 20 shares after the split.

How were X T L Biopharmaceuticals' earnings last quarter?

X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) announced its quarterly earnings data on Wednesday, November, 27th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter. View X T L Biopharmaceuticals' Earnings History.

When is X T L Biopharmaceuticals' next earnings date?

X T L Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for X T L Biopharmaceuticals.

Has X T L Biopharmaceuticals been receiving favorable news coverage?

Headlines about XTLB stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. X T L Biopharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for X T L Biopharmaceuticals.

Who are some of X T L Biopharmaceuticals' key competitors?

What other stocks do shareholders of X T L Biopharmaceuticals own?

Who are X T L Biopharmaceuticals' key executives?

X T L Biopharmaceuticals' management team includes the folowing people:
  • Mr. Joshua Levine, Chief Exec. Officer (Age 53)
  • Mr. Itay Weinstein, Chief Financial Officer (Age 48)
  • Mr. Ronen Kantor Adv, Company Sec.

How do I buy shares of X T L Biopharmaceuticals?

Shares of XTLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is X T L Biopharmaceuticals' stock price today?

One share of XTLB stock can currently be purchased for approximately $1.30.

How big of a company is X T L Biopharmaceuticals?

X T L Biopharmaceuticals has a market capitalization of $6.68 million. View Additional Information About X T L Biopharmaceuticals.

What is X T L Biopharmaceuticals' official website?

The official website for X T L Biopharmaceuticals is http://www.xtlbio.com/.

How can I contact X T L Biopharmaceuticals?

X T L Biopharmaceuticals' mailing address is 5 HACHAROSHET ST., RAANANA L3, 43656. The biopharmaceutical company can be reached via phone at 972-9955-7080 or via email at [email protected]

MarketBeat Community Rating for X T L Biopharmaceuticals (NASDAQ XTLB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about X T L Biopharmaceuticals and other stocks. Vote "Outperform" if you believe XTLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XTLB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel